These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9921409)

  • 21. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
    J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?
    Mathé G; Colasanté U; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(10):473-9. PubMed ID: 9091060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
    Verhofstede C; Van Wanzeele F; Van Der Gucht B; Pelgrom J; Vandekerckhove L; Plum J; Vogelaers D
    J Med Virol; 2007 Sep; 79(9):1254-60. PubMed ID: 17607772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
    Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
    J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Goal of Cancer Treatment.
    Balis FM
    Oncologist; 1998; 3(4):V. PubMed ID: 10388118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing minimal residual malignant disease.
    Mathé G; Reizenstein P
    Oncology; 1986; 43(3):137-42. PubMed ID: 3703458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Resistance to HIV1 infection in exposed uninfected individuals: light and shadow in the research of mechanisms].
    Saez-Cirion A; Scott-Algara D; Pancino G
    Virologie (Montrouge); 2005 Feb; 9(1):55-63. PubMed ID: 34479440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [HIV1 group M superinfection in a HIV1 group0-infected patient].
    Plantier JC; Lemée V; Dorval I; Gueudin M; Braun J; Hutin P; Ruffault A; Curie A; Simon F
    Virologie (Montrouge); 2005 Dec; 9(6):483-486. PubMed ID: 34732008
    [No Abstract]   [Full Text] [Related]  

  • 38. [Control of HIV1 latency by cellular microRNAs].
    Pillet S
    Virologie (Montrouge); 2007 Dec; 11(6):476-477. PubMed ID: 36131472
    [No Abstract]   [Full Text] [Related]  

  • 39. [The influence of CCL3L 1 gene-containing segmental duplications on HIV1 -Aids susceptibility].
    Cuervo N
    Virologie (Montrouge); 2005 Feb; 9(1):69. PubMed ID: 34479444
    [No Abstract]   [Full Text] [Related]  

  • 40. Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1-Infected Patients Treated with Darunavir.
    Opsomer M; Dimitrova D; Verspeelt J; Purrington A; Mehbob A; Chavers S; Pai H; Vanveggel S; Luo D; Brown K; Moecklinghoff C; Nettles RE; Boven K
    Drugs R D; 2018 Sep; 18(3):249-250. PubMed ID: 30079430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.